San Diego, CA -- (SBWIRE) -- 10/12/2016 -- An investigation was announced on behalf of investors of Trinity Biotech plc (ADR) (NASDAQ:TRIB) shares over potential securities laws violations by Trinity Biotech plc and certain of its directors and officers.

Investors who purchased shares of Trinity Biotech plc (ADR) (NASDAQ:TRIB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Trinity Biotech plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On October 4, 2016, pre-market, Trinity Biotech plc announced that it was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the advice of the U.S. Food and Drug Administration. Citing the application withdrawal, Trinity Biotech plc also stated it would reduce its spending from $9 million a year to $1.5 million, and that it would close a Swedish facility, eliminating 40 jobs. Shares of Trinity Biotech plc (ADR) (NASDAQ:TRIB) declined from $13.15 per share on October 3, 2016 to as low as $5.76 per share on October 4, 2016.

On October 11, 2016, NASDAQ:TRIB shares closed at $6.60 per share.

Those who purchased shares of Trinity Biotech plc (ADR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com